Arvinas Inc【ARVN】株式ニュース | ADVFN

US Dollar vs Yen

登録して、同じ考えを持つ投資家と議論するためのアクティブなフォーラムで相互作用するためのアクティブなフォーラムに参加してください。

登録

Arvinas Inc (ARVN)

18.06

0.565

(3.23%)

終了 3月7日 6:00AM

18.05

-0.01

(-0.06%)

取引時間後: 7:50AM

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

プレミアム

Arvinas to Participate in Upcoming Investor Conferences

NEW HAVEN, Conn., March 04, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Form 8-K - Current report

Mr.Mister

Mr.Mister 1日前

Monksdream

Monksdream 6月前

ARVN at a bottom channel

Monksdream

Monksdream 1年前

ARVN new 52=week high

Monksdream

Monksdream 1年前

ARVN new 52 week high

Monksdream

Monksdream 1年前

ARVN new 52 week high

Monksdream

Monksdream 1年前

ARVN new 52 week high

crudeoil24

crudeoil24 4年前

ARVN up 138% > "Based on data to date, we believe ARV-471 is the most promising ER-targeting therapy in the clinic, showing early signs of efficacy, a favorable tolerability profile, and better ER degradation than that previously reported for fulvestrant, the current standard of care,” said Ron Peck, Ph.D., Chief Medical Officer at Arvinas. “It is exciting to see that ARV-110 continues to be active and well tolerated in what we believe is the most heavily pretreated patient population that has ever been studied with an AR-directed therapy. Our recently initiated ARDENT Phase 2 cohort expansion is specifically designed to investigate the potential of a precision medicine approach in molecularly defined, late-line patients with few available treatment options, while also fully characterizing the safety and activity of ARV-110 in earlier line patients irrespective of molecular profile, setting ARV-110 on a potential two-pronged registrational path.”

biocqr

Advantages of PROTACs vs. inhibition...

message_id=152832655

G-lupo

Idk about that, I thought it had some resistance and kept going through, I think at this next convention their going to release some positive news. I’m so holy I didn’t sell at $30 which was ceiling I thought. Do have in a $35 limit sell thought if drops. Rebuy anything under $25

boo boo

boo boo 5年前

Starting to see a chink in the armor!

G-lupo

Possibly wall at 30.50

G-lupo

I feel people are going to start taking profits before $35 price target and give it a dip back.
Question is what is that dip price

boo boo

boo boo 5年前

The offering:

8-k

boo boo

boo boo 5年前

Benzinga 11/14/2019:

With a rating of Buy, Roth Capital initiated coverage on Arvinas Inc (NASDAQ:ARVN). The price target is set at $35.00 for Arvinas. In the third quarter, Arvinas showed an EPS of $0.21, compared to ($62.38) from the year-ago quarter. The current market cap for Arvinas is at $696.1 million. The stock has a 52-week-high of $28.96 and a 52-week-low of $10.19. Arvinas's stock last closed at $28.38 per share.

I might post a chart in about a week, well after everything plays out!

boo boo

boo boo 5年前

It doesn't have to be a PR:

#8

G-lupo

Thanks, I’m in it, thought $28 would be resistant and broke through looks may break $30

boo boo

boo boo 5年前

https://polsonnews.com/arvinas-inc-nasdaqarvn-receives-34-33-average-pt-from-brokerages/

G-lupo

When did they Do a price target announcement? I didn’t see that.

boo boo

boo boo 5年前

If I were in this one (I'm not), I'd be finding the exit on the price target announcement.

G-lupo

Arvn looking good, defintely see $26-27

G-lupo

What you mean IBD?

boo boo

boo boo 5年前

Not me. I look for the trade setup. Learned of this one from IBD and have been following...waiting. Missed the opportunity by 1 day. Would've, Should've, Could've...

G-lupo

I agree I own a decent amount, purchased from $22 down to $15.50. In for the long haul

boo boo

boo boo 5年前

Missing a trade and people who post a purchase at a specific price well after that price has passed.

The bottom of the prior range (July thru September) is resistance as far as I'm concerned and you have a couple important SMA's around there. And I agree that a break of $27 could lead to a higher price. Wouldn't be as confident if a press release occurred at the same time, but then again depends on what is said.

G-lupo

What are you talking about ?

Saw the rebound at $16, going to get probably Around $25-26, if gets there look for resistance to drop back. Like this stock and with more news if breaks $27 could see $60

boo boo

boo boo 5年前

Screwed this one up. More and better content on biotech values board. And no, I don't think this individual bought 'yesterday' and posted about it the day after. That's crap and not credible...POSER!

boo boo

boo boo 5年前

boo boo

boo boo 5年前

Price is at the 100 Lower Linear Regression channel. Do we consolidate here and eventually move north. No position...yet!

PennyStock Alert

PennyStock Alert 6年前

G-lupo

This stock very volatile, no rhyme or reason why it’s been up and down.

morokoy

morokoy 6年前

Las Vegas man 1st in world to use new experimental cancer drug, ARV 101.

https://www.reviewjournal.com/life/health/las-vegas-man-1st-in-world-to-use-new-experimental-cancer-drug-video-1654750/

Direxion Daily Semicondu...

Sparta Infra Cdi Ficfi I...

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約